Brady Maher

Brady Maher, PhD, is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine. His research focuses on the molecular and cellular mechanisms of neurodevelopmental and psychiatric disorders, including autism spectrum disorder (ASD), schizophrenia, and Pitt-Hopkins syndrome (PTHS). He leads a laboratory dedicated to understanding the role of the Transcription Factor 4 (TCF4) gene in brain development and dysfunction.

His research interests lie at the intersection of Developmental Neuroscience, Systems and Cognitive Neuroscience, Neural Circuits, and Neurobiology of Disease. Using patient-derived induced pluripotent stem cells (iPSCs), animal models, and CRISPR/Cas9 technology, his lab investigates how TCF4 regulates cortical development, neuronal excitability, interneuron connectivity, and myelination. A central finding is that TCF4 mutations disrupt oligodendrocyte development, suggesting myelination deficits may be a common mechanism in autism spectrum disorders.

The recent publications highlight a strong trend in neurodevelopmental genetics, hiPSC-based disease modeling, and myelination pathology. His work bridges molecular genetics with functional neuroscience, aiming to identify therapeutic targets for psychiatric and neurodevelopmental conditions. Key themes include synaptic dysfunction, neuronal excitability, and the translation of iPSC findings to clinical phenotypes in schizophrenia and ASD.

Scientific Awards:
None listed in the provided text.

Dr. Maher is actively involved in mentoring and research training, particularly through his affiliation with the Neuroscience Training Program at Johns Hopkins. His lab secures funding to support innovative projects using cutting-edge technologies like iPSC modeling and CRISPR editing. While specific grant details are not mentioned, the scope and impact of his publications suggest substantial research support. He collaborates extensively with clinical and computational neuroscientists, as evidenced by co-authorships with experts in genomics, electrophysiology, and psychiatric phenotyping.

His laboratory functions as an interdisciplinary team combining molecular biology, stem cell technology, and systems neuroscience to unravel the pathophysiology of complex brain disorders. The lab generates and characterizes patient-specific iPSC lines and uses them to model diseases like PTHS and schizophrenia, aiming to develop novel therapeutic strategies.